Product Development Associate - Therapeutics

Company: Fannin

Location: Houston, TX (On-Site) 

About Fannin 

Fannin is an early-stage life sciences product development company that partners with academic researchers, innovators, and clinicians to advance impactful therapeutics and medical technologies. Working across internally developed programs and assets in-licensed from leading institutions, we build fund and operate new biotech and medtech ventures, leveraging both grant and investor funds. Our team brings deep expertise across drug development, translational science, and commercialization, and works hands-on to move promising science toward the clinic. 

Please see below for more information about major Fannin programs and pipeline. 

Role Overview 

We are seeking a scientifically strong, execution-oriented Product Development Associate (Therapeutics) to lead and advance early-stage drug development programs within Fannin’s portfolio. This role is ideal for early-career MDs, PhDs, postdocs, or clinically trained scientists interested in translational medicine, IND-enabling development, and biotech company building. 

You will serve as the program lead for one or more therapeutic assets, working closely with Fannin leadership to drive strategy, design critical path development plans, manage external partners, and deliver high-quality decision-making materials. You will gain broad exposure across research, product development, business development, and operations in a fast-paced, mission-driven environment. 

Key Responsibilities 

Scientific & Program Leadership 

• Evaluate preclinical and translational data; guide experimental design and development strategy. 
• Identify risks, gaps, opportunities, and inflection points that shape program direction. 
• Maintain ownership of timelines, milestones, and deliverables across multiple active programs. 

External Execution & Collaboration 

• Manage relationships with academic collaborators and contract research organizations (CROs). 
• Represent programs in internal reviews, scientific discussions, partner meetings, and presentations. 
• Support due diligence, competitive assessments, and translational feasibility analyses for potential in-licensing opportunities. 

Funding & Strategic Contributions: 

• Lead or support development of non-dilutive funding submissions (e.g., NIH SBIR). 
• Prepare concise, compelling scientific materials including slide decks, decision memos, and investor-oriented summaries. 

Team & Culture

• Provide guidance for interns and junior team members. 
• Contribute to shared operational and cultural activities that strengthen the Fannin organization. 
• Model scientific rigor, collaborative behavior, and adaptability. 

Qualifications

Education 

• Ph.D., M.D., or equivalent in a life-sciences field (e.g., molecular/cell biology, immunology, pharmacology, pharmaceutical sciences, radiochemistry, medicinal chemistry). 

Skills & Attributes 

• Strong scientific judgment and ability to interpret complex data. 
• Excellent analytical, writing, and communication skills. 
• Comfortable working across multiple programs in a fast-moving, dynamic environment. 
• Resourceful, adaptable, and proactive with a strong bias toward execution. 
• Collaborative mindset; eager to learn and open to coaching. 

What We Offer 

• Direct ownership and day-to-day leadership of meaningful therapeutic programs across discovery, pre-clinical, IND-enabling, and clinical development, depending on portfolio needs. 
• Hands-on mentorship from experienced biotech operators, drug developers, and executives. 
• Broad exposure across translational research, clinical strategy, regulatory planning, and external partnerships. 
• Opportunities to work across multiple therapeutic modalities, including biologics, small molecules, targeted ligands, and radiotherapeutics. 
• A mission-driven environment focused on advancing new therapies for patients with unmet needs. 

How to Apply 

Please submit your resume and a short cover letter describing your interest and qualifications through Our Applications Portal https://shorturl.at/lP81x 

Major Fannin Programs & Companies 

Fannin advances a diverse portfolio of therapeutics and technology platforms across biologics, small molecules, targeted ligands, radiotherapeutics, and medical devices. Product Development Associates may contribute directly to several of the internally managed or actively supported therapeutic programs below. 3 

Fannin-Managed or Actively Supported Therapeutic Programs 

These are programs and companies—whether internal or independently incorporated—where Fannin team members play key operational, strategic, or leadership roles. 

Allterum Therapeutics 

A clinical-stage company developing targeted therapies for oncology and autoimmune indications. The lead asset, 4A10, is an anti-CD127 monoclonal antibody licensed from the NCI for the treatment of acute lymphoblastic leukemia (ALL), B-cell malignancies, lymphomas, and relapsed or refractory solid tumors that overexpress CD127. 

Goldenrod Therapeutics 

Developing selective PDE4 inhibitors for neurodegenerative diseases and substance use disorder. The small-molecule lead asset, 11h, licensed from the University of Nebraska, is currently in IND-enabling studies. 

AIRR 

Advancing an inhibitor of MAP4K4 for diseases involving ischemia-reperfusion injury. The small-molecule lead asset, DMX5804, licensed from Imperial College London, is preparing to enter IND-enabling studies for myocardial infarction and kidney protection during resection and percutaneous coronary intervention (PCI). 

Brimstalt Therapeutics 

Developing conditionally active, targeted anti-cancer agents. The lead programs focus on optimizing drugs activated by a tumor-associated enzyme (TAE). 

Raptamer Discovery Group (RDG) 

A discovery platform using Raptamers—peptidomimetic DNA ligands—to develop highly selective, targeted therapeutics across multiple disease areas and molecular targets. 

Cevira 

Developing a Raptamer Drug-Conjugate (RapDC) targeting CD127 for the treatment of CD127-expressing cancers and autoimmune diseases. The lead asset is scheduled to enter IND-enabling studies in Q1 2026. 

Radiomer Therapeutics 

A theranostic company developing radioligand therapies and imaging agents using Raptamers for targeted delivery of alpha- and beta-emitting radionuclides. The lead asset is planned to enter Phase 0 dosimetry studies in 2026. 

Angira 

Developing a first-in-class anti-angiogenic therapeutic for macular degeneration and additional ophthalmic indications. IND-enabling studies for the lead asset are expected to begin in 2026. 

Independent Fannin-Established Companies 

These companies were established by Fannin and now operate independently, with ongoing strategic or historical ties. 

Procyrion 

Developing a percutaneous mechanical circulatory support (pMCS) device for heart failure patients who are too sick for medical therapy alone. The lead device, Aortix, is in pivotal clinical studies for cardiorenal syndrome.

Pulmotect 

A clinical-stage company developing an inhaled therapy that activates innate lung immunity to provide rapid protection against viral, bacterial, and fungal respiratory pathogens. The lead asset, PUL-042, is in a randomized, placebo-controlled Phase 2b trial in immunocompromised cancer patients. 

Brevitest 

Developing a point-of-care, miniaturized analyzer capable of quantifying multiple biomarkers from a small blood sample on a single disposable cartridge. The platform’s first product, Bioscale, is preparing for launch in the wellness market.